STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2167 by analyst upside · 2026-08-13
ERAS
Erasca, Inc.
Healthcare · Market Cap $6B · P/E 0x
ANALYST PRICE TARGET
+23.2%
implied upside to consensus target
Current Price $18.58
Consensus Target $22.89
Bull Target $30.0
Bear Target $18.0
Analysts Covering 9
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
6
Hold
2
Sell
0
52-Week Low $1.33
52-Week High $24.28
YTD Return +417.5%
FUNDAMENTALS
Market Cap $6B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.95
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.33
52-Week High $24.28
Current Price $18.58
Bear Target $18.0
Bull Target $30.0
● Now $18.58 ● Target $22.89
TRADING DATA
Avg Volume 5.0M
YTD Return +417.5%
Analyst Count 9
Consensus Buy
Upside to Target +23.2%
Last Updated 2026-08-13

ANALYST SUMMARY

Erasca, Inc. (ERAS) is currently trading at $18.58 with a Wall Street consensus price target of $22.89, implying potential upside of 23.2% over the next 12 months. 9 analysts currently cover ERAS, with a consensus rating of Buy - 78% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $30.0, while the most cautious has a target of $18.0.

ERAS operates in the Healthcare sector with a market capitalisation of $6B. The stock is up 417.5% year-to-date and is currently trading near the upper end of its 52-week range of $1.33 – $24.28.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ERAS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

B of A Securities ↑ Upgrade
Underperform → Neutral 2026-06-04 Building track record
Mizuho - Reiterated
Outperform → Outperform 2026-05-12 Building track record
Stifel - Reiterated
Buy → Buy 2026-04-27 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-03-18 43% win rate (7 calls)
Guggenheim - Reiterated
Buy → Buy 2026-03-16 62% win rate (8 calls)
Piper Sandler - Reiterated
Overweight → Overweight 2026-03-13 14% win rate (7 calls)
Mizuho - Reiterated
Outperform → Outperform 2026-03-13 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-03-13 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
49
out of 100
Coverage depth
18/30
Consensus clarity
17/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →